Drugs / Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04178577 | Dec 2019 → Sep 2020 | impaired renal function disease | Spero Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04178577 ↗ |
| Route | Oral | “Subjects in cohorts 1 to 4 received a single oral dose of TBP-PI-HBr (600 mg).” PMID 35420493 ↗ Apr 2022 |